Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02971956
Title A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

esophagus adenocarcinoma

esophagus squamous cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.